We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nu Holdings Ltd. (NU) - free report >>
Vericel Corporation (VCEL) - free report >>
Enlivex Therapeutics Ltd. (ENLV) - free report >>
Image: Bigstock
New Strong Buy Stocks for October 19th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Intapp, Inc.(INTA - Free Report) : This company which provides industry-specific, cloud-based software solutions which enable connected professional and financial services firms, has seen the Zacks Consensus Estimate for its current year earnings increasing 35.3% over the last 60 days.
Intapp, Inc. Price and Consensus
Intapp, Inc. price-consensus-chart | Intapp, Inc. Quote
Nu Holdings Ltd. (NU - Free Report) : This company which provides digital banking and technology platform, has seen the Zacks Consensus Estimate for its current year earnings increasing 23.5% over the last 60 days.
Nu Holdings Ltd. Price and Consensus
Nu Holdings Ltd. price-consensus-chart | Nu Holdings Ltd. Quote
Enlivex Therapeutics Ltd. (ENLV - Free Report) : This is a clinical stage immunotherapy company, has seen the Zacks Consensus Estimate for its current year earnings increasing 19.1% over the last 60 days.
Enlivex Therapeutics Ltd. Price and Consensus
Enlivex Therapeutics Ltd. price-consensus-chart | Enlivex Therapeutics Ltd. Quote
Vericel Corporation (VCEL - Free Report) : This company which focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, has seen the Zacks Consensus Estimate for its current year earnings increasing 17.9% over the last 60 days.
Vericel Corporation Price and Consensus
Vericel Corporation price-consensus-chart | Vericel Corporation Quote
BioVie Inc. (BIVI - Free Report) : This company which engages in developing drug therapies for liver disease, has seen the Zacks Consensus Estimate for its current year earnings increasing 12.7% over the last 60 days.
BioVie Inc. Price and Consensus
BioVie Inc. price-consensus-chart | BioVie Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.